About us
Vision & Mission
The Pediatric Praziquantel Consortium is an international partnership that aims to improve child health. Our goal is to reduce the global disease burden of schistosomiasis by addressing the medical needs of infected preschool-age children. The neglected tropical disease affects approximately 240 million people worldwide, including an estimated 50 million preschool-age children that are currently lacking adequate treatment. The Consortium operates on a not-for-profit basis.
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical needs of infected preschool-age children including infants and toddlers.
Our mission is to develop, register, and provide access to a suitable pediatric treatment option for preschool-age children affected by schistosomiasis.
To accomplish our mission:
- We combine some of the best science and most experienced public and private partners to develop and provide a suitable pediatric treatment for schistosomiasis. Read more
- We operate through an innovative approach that engages new partners as needed. Beyond the partners contributing expertise and resources, we proactively promote dialogue at all stakeholder levels and consult international academics, experts from endemic countries, funding agencies, the WHO, and non-governmental organizations. Read more
- Our clinical program, completed at the end of 2021, comprised a full phase I-III development program, set up in line with European Medicines Agency (EMA) recommendations for pediatric development. It was designed with the support of regulatory authorities and a panel of international experts, including clinicians from endemic countries. Read more
- Once approved, the potential new pediatric treatment option will be made available on a not-for-profit basis. Together with relevant stakeholders, we are exploring new procurement and business models, including local manufacturing, to ensure equitable and sustainable access to the product for the young patients in need. Read more